FDA 483 OBSERVATION · #950 OF 1,000 MOST-CITED
Circumstances of obtaining consent
FDA cited this observation 14 times across 13 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
How FDA worded it — real examples
The general requirements for informed consent were not met in that you did not seek consent under circumstances that provided the prospective subject or the subject's representative sufficient opportunity to consider whether or not to participate and minimized the possibility of coercion or undue influence.
The general requirements for informed consent were not met in that you did not seek consent under circumstances that minimized the possibility of coercion or undue influence.
The general requirements for informed consent were not met in that you and the investigator did not seek consent under circumstances that minimized the possibility of coercion or undue influence.
The general requirements for informed consent were not met in that you did not seek consent under circumstances that provided the prospective subject or the subject's representative sufficient opportunity to consider whether or not to participate and minimized the possibility of coercion or undue influence.
The general requirements for informed consent were not met in that you did not seek consent under circumstances that provided the prospective subject or the subject's representative sufficient opportunity to consider whether or not to participate.
The general requirements for informed consent were not met in that you did not seek consent under circumstances that minimized the possibility of coercion or undue influence.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.